Science News

... from universities, journals, and other research organizations

Hope for More Options in Couples Where One Partner Is HIV Positive

Nov. 28, 2011 — In sub-Saharan Africa, couples in long-term relationships where one partner is HIV-positive and the other is HIV-negative (HIV serodiscordant couples) could benefit from anti-AIDS drugs (antiretroviral therapy) given either as treatment or as a prevention measure (prophylaxis) to reduce the risk of HIV transmission. These findings, from a modelling study led by Timothy Hallett from Imperial College London and published in this week's PLoS Medicine, also show that this strategy could be cost-effective.


Share This:

In sub-Saharan Africa, where most new HIV infections occur and condom use is often low, 10-20% of stable partnerships are serodiscordant. The authors used detailed information and specific data from South Africa to construct a model to simulate HIV infection and disease progression among hypothetical HIV serodiscordant couples in stable heterosexual relationships. The authors used the model to compare the impact on HIV transmission, survival and quality of life and the cost-effectiveness of different prophylaxis strategies.

To keep couples alive without the HIV-uninfected partner becoming infected, the authors found that it could be at least as cost-effective to provide prophylaxis to the uninfected partner as to initiate antiretroviral therapy earlier than current guidelines in the infected partner. Specifically, the most cost-effective strategy for couples could be to use prophylaxis in the uninfected partner prior to starting antiretroviral therapy in the infected partner.

These findings suggest that prophylaxis may become a valuable addition, in some settings, to existing approaches for HIV prevention such as condom promotion, male circumcision programs and anti-retroviral treatment.

The authors say: "We hope [these findings] might inform the choices that will be available for HIV prevention in couples. We note, however, that it is important that many other considerations besides cost effectiveness should inform decision-making for HIV treatment initiation and provision of [prophylaxis] in couples, including equitable access and the preferences of the couples themselves."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Public Library of Science.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Timothy B. Hallett, Jared M. Baeten, Renee Heffron, Ruanne Barnabas, Guy de Bruyn, Íde Cremin, Sinead Delany, Geoffrey P. Garnett, Glenda Gray, Leigh Johnson, James Mcintyre, Helen Rees, Connie Celum. Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. PLoS Medicine, 2011; 8 (11): e1001123 DOI: 10.1371/journal.pmed.1001123
APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,221

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Cleaning Infected Blood

Infectious disease experts designed a machine called the hemopurifier. It works much like a dialysis machine, using thin fibers to capture and remove. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: